Corvus Pharmaceuticals, Inc. Aktie News

Daten stützen laufende Zulassungsstudie der Phase 3 bei r/r PTCL, Phase‑2‑Studie bei atopischer Dermatitis und geplante Studien für Hidradenitis suppurativa und Asthma Daten bei T‑Zell‑Lymphomen zeigten antitumorale Aktivität basierend auf tumorintrinsischen und tumorextrinsischen Effekten auf das Mikroumfeld Highlights ITK‑Hemmung neuartiger Wirkmechanismus, abgestimmt mit kürzlich präsentie...

Die Rekrutierung in der zulassungsrelevanten Phase-3-Studie zu soquelitinib bei rezidivierter/refraktärer peripherer T-Zell-Lymphom (PTCL) und in der Phase-2-Studie zu atopischer Dermatitis verläuft planmäßig Das Potenzial von soquelitinib bei atopischer Dermatitis und weiteren Indikationen in Immunologie und Entzündung wird durch Phase-1-klinische, immunologische und Biomarker-Daten unterstütz...

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States $13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, whic...

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual...

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and ...

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for Investigative Dermatology (SID) annual meeting Company hosting investor and analyst meeting to review SID data...

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he l...